- Home
- DNA vs NXP Comparison
DNA vs NXP Comparison
Compare DNA & NXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DNA | NXP |
|---|---|---|
| Founded | 2008 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 835.7M | 898.0M |
| IPO Year | 2020 | 1995 |
Fundamental Metrics
Financial Performance| Metric | DNA | NXP |
|---|---|---|
| Price | $11.22 | $13.04 |
| Analyst Decision | Sell | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 3.0M | 369.8K |
| Earning Date | 11-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46.49 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $170,155,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $13.37 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.37 | $12.87 |
| 52 Week High | $18.22 | $14.65 |
Technical Indicators
Market Signals| Indicator | DNA | NXP |
|---|---|---|
| Relative Strength Index (RSI) | 56.80 | 36.05 |
| Support Level | $6.86 | $12.87 |
| Resistance Level | N/A | $14.44 |
| Average True Range (ATR) | 1.63 | 0.26 |
| MACD | 0.20 | 0.00 |
| Stochastic Oscillator | 35.01 | 13.34 |
Price Performance
Historical ComparisonAbout DNA Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
About NXP Nuveen Select Tax Free Income Portfolio
Nuveen Select Tax Free Income Portfolio is a closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax, consistent with preservation of capital. The fund has single operating segment.